Background
==========

Following the identification of the *APOE*ε4 allele as a risk factor for late-onset Alzheimer\'s disease (LOAD) in 1993 \[[@B1]\], consistent replication of subsequently identified candidates was not achieved until 2009, when two genome-wide association studies (GWAS) \[[@B2],[@B3]\] identified associations of variants in or near *CLU, PICALM*, and *CR1*with LOAD, which were consistently replicated in multiple large, independent case-control studies \[[@B4]-[@B17]\]. Subsequently, a variant near *BIN1*was reported \[[@B4]\] to achieve genome-wide significant association in a later GWAS published in 2010 that also replicated well in follow-up studies \[[@B14]-[@B19]\]. These results demonstrate the utility of the hypothesis-free GWAS approach for identifying loci that associate with LOAD and the necessity of pooling samples and data from multiple centers to obtain resources with sufficient statistical power (GWAS typically \> 14,000, follow-up typically total \> 28,000) to detect the modest ORs (e.g. 0.8/1.2) associated with these variants in GWAS and follow-up studies.

Two recently published companion studies by Hollingworth *et al*. \[[@B20]\] and Naj *et al*. \[[@B17]\] performed meta-analysis of two large GWAS datasets (n \> 75,000). Besides *APOE, CLU, PICALM*, and *CR1*, the meta-analyses revealed association at *ABCA7*(p = 5 × 10^-21^), *MS4A6A*(p = 1.2 × 10^-16^), *MS4A4E*(p = 1.1 × 10^-10^), *EPHA1*(p = 6 × 10^-10^), *CD2AP*(p = 8.6 × 10^-9^) and *CD33*(p = 1.6 × 10^-9^). In addition, the two datasets revealed opposing association (Naj *et al*. OR = 0.93, p = 0.001; Hollingworth *et al*. OR = 1.06, p = 0.03) of the variant near *ARID5B*(rs2588969) with LOAD, suggesting potential heterogeneity at this locus. In this study, we genotyped the variants identified at the *CD2AP, EPHA1*, and *CD33*loci in our independent case-control dataset comprising six case-control series (n = 6,835). To assess the opposing associations at the *ARID5B*locus, we also genotyped the two *ARID5B*variants included in the Hollingworth *et al*. study. Genotypes from our follow-up case-control series (Mayo 2) for variants in *ABCA7, MS4A6A*and *MA4A4E*were included in Stage 3 of the Hollingworth *et al*. study, so we have not included these three variants in this study. We have performed meta-analyses of five variants (at *CD2AP, EPHA1, ARID5B*and *CD33*loci) in our six case-control series, which showed no significant series heterogeneity. Furthermore, we have performed logistic regression analysis of our pooled series adjusting for covariates. Finally, we have used a Fisher\'s combined test to evaluate the significance of the association of these five variants in our data combined with the data in the Hollingworth *et al*. and Naj *et al*. studies.

Results
=======

We genotyped five variants (*CD2AP*; rs9349407, *EPHA1*; rs11767557, *ARID5B*; rs2588969 and rs4948288, *CD33*; rs3865444) in our independent follow-up case-control series (Mayo2) from three North American and three European Caucasian series. Detailed information about these samples is shown in Table [1](#T1){ref-type="table"} and genotype counts are shown in Table [2](#T2){ref-type="table"}. Samples used in this study do not overlap with those included in the Naj *et al*. study and have not been included in any of the published LOAD GWAS. The Mayo2 dataset included in the Hollingworth *et al*. publication only included genotypes for *ABCA7, MS4A6A*and *MA4A4E*.

###### 

Details of the Mayo2 samples used in this study and genotype counts

                 Number of samples   Mean Age (SD)   \% Female   \% ε4+                                         
  -------------- ------------------- --------------- ----------- ------------ ------------ ------ ------ ------ ------
  Jacksonville   507                 967             1,474       80.0 (6.7)   81.7 (7.6)   61.9   56.3   60.2   21.8
  Rochester      317                 1,638           1,955       85.8 (4.5)   80.3 (5.2)   62.1   54.6   42.3   22.4
  Autopsy        312                 102             414         87.4 (4.8)   86.0 (4.3)   67.6   52.0   61.2   14.7
  Norway         346                 555             901         80.2 (7.3)   75.3 (6.8)   69.9   59.8   63.0   24.1
  Poland         483                 188             671         76.7 (4.8)   73.0 (5.9)   66.3   76.6   56.4   19.0
  ARUK           669                 751             1,420       75.6 (8.2)   76.2 (7.3)   55.6   49.9   58.0   24.4

The number of LOAD patients (AD) and controls (CON), mean age-at-diagnosis, percentage that are female and percentage that possess at least one copy of the *APOE ε*4 allele are given for each individual series. Mean age is given as age at diagnosis/entry with the standard deviation (SD) from the mean in parentheses. None of the samples comprising the Jacksonville, Rochester and autopsy-confirmed Mayo Clinic or ARUK series (comprising Bristol, Leeds, Manchester, Nottingham, Oxford and Southampton), which were included in this follow-up study overlap with those used in the Naj *et al*. study and have not been included in any of the published LOAD GWAS. The Mayo2 dataset included in the Hollingworth *et al*. publication only included genotypes for *ABCA7, MS4A6A*and *MA4A4E*.

###### 

Genotype counts for each of the six Mayo2 series

                 *CD2AP*(rs9349407)   *EPHA1*(rs11767557)   *ARID5B*(rs2588969)   *ARID5B*(rs4948288)   *CD33*(rs3865444)                                                                  
  -------------- -------------------- --------------------- --------------------- --------------------- ------------------- --------------- -------------- --------------- --------------- ---------------
  Jacksonville   254/197/41           497/369/56            339/143/19            612/301/44            188/226/81          379/400/149     164/233/99     351/426/148     251/200/41      446/386/88
  Rochester      170/126/17           843/640/117           198/102/9             985/518/69            100/159/48          623/755/226     92/172/50      581/748/250     148/134/30      715/692/170
  Autopsy        156/110/19           49/44/7               205/97/5              61/28/10              118/148/42          50/38/14        115/142/43     38/43/17        141/125/32      42/44/11
  Norway         177/131/16           273/205/41            212/113/13            337/185/26            129/165/44          215/250/78      115/156/53     184/268/88      153/139/35      248/236/57
  Poland         235/193/40           100/70/11             297/140/20            108/52/9              153/243/77          65/91/29        160/222/84     62/96/26        224/204/39      96/83/8
  ARUK           341/243/55           363/317/53            386/191/20            439/234/37            236/313/101         271/367/102     208/326/122    259/351/122     289/286/67      329/307/94
  Total          1333/1000/188        2125/1645/285         1637/786/86           2542/1318/195         924/1254/393        1603/1901/598   854/1251/451   1475/1932/651   1206/1088/244   1876/1748/428

The genotype counts (major allele homozygotes/heterozygotes/minor allele homozygotes) for *CD2AP*(rs9349407), *EPHA1*(rs11767557), *ARID5B*(rs2588969 and rs4948288) and *CD33*(rs3865444) variants are given for each individual series.

Meta-analyses of allelic association in the six Mayo2 series performed using a DerSimonian-Laird random effects model (Figure [1](#F1){ref-type="fig"}) revealed a significant pooled OR for the *EPHA1*variant (Figure [1b](#F1){ref-type="fig"}; OR = 0.88, p = 0.008) comparable to that previously published by Naj *et al*. (OR = 0.87) and by Hollingworth *et al*. (OR = 0.90). As shown in Figure [1c](#F1){ref-type="fig"} and [1d](#F1){ref-type="fig"}, we also observed significant association for both *ARID5B*variants (rs2588969, OR = 1.08, p = 0.046; rs4948288, OR = 1.11, p = 0.008) with ORs comparable to those reported by Hollingworth *et al*. (OR = 1.06 and 1.07, respectively) and in the opposing direction to those reported by Naj *et al*. for rs2588969 (Stage 1+2 OR = 0.93, p = 7.7 × 10^-4^). As shown in Figure [1a](#F1){ref-type="fig"} and [1e](#F1){ref-type="fig"}, we did not observe significant association for *CD2AP*(OR = 0.98, p = 0.76) or *CD33*(OR = 0.96, p = 0.32) in our meta-analyses. Breslow-Day tests provided no significant evidence that the ORs for any of these variants were heterogeneous among our series (all p \> 0.25), as shown in Figure [1](#F1){ref-type="fig"}. The variant with the most heterogeneity was *CD2AP*(rs9349407) where the estimated percentage of variation due to heterogeneity across studies (I^2^) was 25.1% (95% CI 0%-70%) suggesting the presence of some heterogeneity for that variant.

![**Forest plots for meta-analysis of *CD2AP, EPHA1, ARID5B*, and *CD33*variants in our six Mayo2 case-control series**. ORs (boxes) and 95% CI (whiskers) are plotted for each population and shown on the right of each plot. Combined OR is the overall OR calculated by the meta-analysis using a random effects model. P-values are provided for the combined ORs and Breslow-Day tests of heterogeneity. I2 gives an estimate of between studies variance.](1750-1326-6-54-1){#F1}

To adjust for important covariates, we included age-at-diagnosis/entry, sex and *APOE ε 4*dosage in logistic regression analyses of all five variants in each of the six Mayo2 series; in our analysis of all Mayo2 series combined, series was included as an additional covariate. Table [3](#T3){ref-type="table"} shows the results for the six Mayo2 series combined (Mayo follow-up) as well as for each of the six individual Mayo2 series. For the purpose of comparison, we have also included in Table [3](#T3){ref-type="table"} the published GWAS results for the same variants. Adjustment for covariates revealed comparable ORs to those obtained in the meta-analyses, with improved p-values for the *EPHA1*(OR = 0.87, p = 5 × 10^-4^), *CD33*(OR = 0.92, p = 0.049) and *CD2AP*(OR = 0.97, p = 0.56) loci. However, the associations of the *ARID5B*variants were no longer significant following adjustment for covariates (rs2588969: OR = 1.05, p = 0.30, rs4948288: OR = 1.07, p = 0.11) suggesting that these associations may be dependent upon the series, age-at-diagnosis/entry, sex and/or *APOE ε 4*dosage of the individual.

###### 

Association of *CD2AP, EPHA1, ARID5B*, and *CD33*variants with LOAD in the initial studies (ADGC and GERAD+) and Mayo2 follow-up series

                                              *N*^a^   MAF^b^   Association test                             
  ------------------------------------------- -------- -------- ------------------ ------ ------------------ ------------------
  ***CD2AP-*rs9349407-C (minor) allele**                                                                     
                                                                                                             
  ADGC Discovery (Stage 1)                    8,309    7,366                              1.14 (1.08-1.21)   **1.2 × 10^-6^**
  ADGC Replication (Stage 2)                  3,531    3,565                              1.07 (0.98-1.17)   **0.12**
  ADGC combined analysis (Stages 1+2)         11,840   10,931                             1.12 (1.07-1.18)   **1.0 × 10^-6^**
  Hollingworth *et al*. (GERAD + Consortia)   6,283    7,165                              1.11 (1.04-1.18)   **8 × 10^-4^**
  Mayo2^c^                                    2,521    4,055    0.27               0.27   0.97 (0.89-1.07)   0.56
  Jacksonville                                492      922      0.28               0.26   1.10 (0.91-1.33)   0.34
  Rochester                                   313      1,600    0.26               0.27   0.88 (0.70-1.09)   0.24
  Autopsy                                     285      100      0.26               0.29   0.98 (0.65-1.47)   0.92
  Norway                                      324      519      0.25               0.28   0.81 (0.62-1.06)   0.13
  Poland                                      468      181      0.29               0.25   1.04 (0.77-1.42)   0.79
  ARUK                                        639      733      0.28               0.29   0.97 (0.81-1.16)   0.72
  ADGC/Hollingworth^d^                        18,123   18,096                                                1.2 × 10^-10^
  Mayo2/ADGC/Hollingworth^e^                  20,644   22,151                                                6.5 × 10^-11^
                                                                                                             
  ***EPHA1-*rs11767557-C (minor) allele**                                                                    
                                                                                                             
  ADGC Discovery (Stage 1)                    8,309    7,366                              0.85 (0.80-0.90)   **7.3 × 10^-8^**
  ADGC Replication (Stage 2)                  3,531    3,565                              0.94 (0.86-1.03)   0.17
  ADGC combined analysis (Stages 1+2)         11,840   10,931                             0.87 (0.83-0.92)   **2.4 × 10^-7^**
  Hollingworth et al (GERAD + Consortia)      6,283    12,935                             0.90 (0.85-0.95)   **3.4 × 10^-4^**
  Mayo2^c^                                    2,509    4,055    0.19               0.21   0.87 (0.78-0.96)   **5.5 × 10^-4^**
  Jacksonville                                501      957      0.18               0.20   0.86 (0.70-1.06)   0.17
  Rochester                                   309      1,572    0.19               0.21   0.89 (0.69-1.13)   0.33
  Autopsy                                     307      99       0.17               0.24   0.66 (0.43-1.02)   0.06
  Norway                                      338      548      0.21               0.22   0.94 (0.71-1.24)   0.67
  Poland                                      457      169      0.20               0.21   0.93 (0.66-1.31)   0.67
  ARUK                                        597      710      0.19               0.22   0.85 (0.69-1.04)   0.12
  ADGC/Hollingworth^d^                        18,123   18,096                                                4.2 × 10^-12^
  Mayo2/ADGC/Hollingworth^e^                  20,632   27,921                                                2.1 × 10^-15^
                                                                                                             
  ***ARID5B-*rs2588969-A (minor) allele**                                                                    
                                                                                                             
  ADGC Discovery (Stage 1)                    8,309    7,366                              0.88 (0.84-0.93)   **1.1 × 10^-6^**
  ADGC Replication (Stage 2)                  3,531    3,565                              1.05 (0.97-1.13)   0.23
  ADGC combined analysis (Stages 1+2)         11,840   10,931                             0.93 (0.89-0.97)   **0.001**
  Hollingworth et al (GERAD + Consortia)      6,283    7,165                              1.06 (1.01-1.13)   **0.03**
  Mayo2^c^                                    2,571    4,102    0.40               0.38   1.05 (0.96-1.14)   0.30
  Jacksonville                                495      928      0.39               0.38   1.04 (0.88-1.23)   0.63
  Rochester                                   307      1,604    0.42               0.38   1.12 (0.92-1.37)   0.26
  Autopsy                                     308      102      0.38               0.32   1.24 (0.86-1.79)   0.24
  Norway                                      338      543      0.37               0.37   1.05 (0.83-1.33)   0.69
  Poland                                      473      185      0.42               0.40   0.91 (0.68-1.20)   0.49
  ARUK                                        650      740      0.40               0.39   1.05 (0.88-1.24)   0.61
  ADGC/Hollingworth^d^                        18,123   18,096                                                7.6 × 10^-9^
  Mayo2/ADGC/Hollingworth^e^                  20,694   22,198                                                2.3 × 10^-9^
                                                                                                             
  **ARID5B-rs4948288-A (minor) allele**                                                                      
                                                                                                             
  ADGC Discovery (Stage 1)                    8,309    7,366                                                 
  ADGC Replication (Stage 2)                  3,531    3,565                                                 
  ADGC combined analysis (Stages 1+2)         11,840   10,931                                                
  Hollingworth et al (GERAD + Consortia)      6,992    13,472                             1.07 (1.03-1.15)   **3.6 × 10^-3^**
  Mayo2^c^                                    2,556    4,058    0.42               0.40   1.07 (0.99-1.16)   0.11
  Jacksonville                                496      925      0.43               0.39   1.13 (0.96-1.34)   0.14
  Rochester                                   314      1,579    0.43               0.40   1.08 (0.89-1.32)   0.43
  Autopsy                                     300      98       0.38               0.39   0.91 (0.63-1.32)   0.61
  Norway                                      324      540      0.40               0.41   1.06 (0.83-1.34)   0.64
  Poland                                      466      184      0.42               0.40   0.90 (0.68-1.20)   0.48
  ARUK                                        656      732      0.43               0.41   1.13 (0.96-1.33)   0.14
  Mayo2/ADGC/Hollingworth^e^                  9,548    17,530                                                4.0 × 10^-4^
                                                                                                             
  ***CD33 -*rs3865444-A (minor) allele**                                                                     
                                                                                                             
  ADGC Discovery (Stage 1)                    8,309    7,366                              0.88 (0.84-0.93)   **8.2 × 10^-7^**
  ADGC Replication (Stage 2)                  3,531    3,565                              0.91 (0.85-0.99)   **0.02**
  ADGC combined analysis (Stages 1+2)         11,840   10,931                             0.89 (0.86-0.93)   **1.1 × 10^-7^**
  Hollingworth et al (GERAD + Consortia)      6,283    7,165                              0.89 (0.84-0.95)   **2.2 × 10^-4^**
  Mayo2^c^                                    2538     4052     0.31               0.32   0.92 (0.84-1.00)   **4.9 × 10^-2^**
  Jacksonville                                492      920      0.29               0.31   0.82 (0.68-0.98)   **0.03**
  Rochester                                   312      1,577    0.31               0.33   0.88 (0.72-1.08)   0.23
  Autopsy                                     298      97       0.32               0.34   0.84 (0.57-1.24)   0.39
  Norway                                      327      541      0.32               0.32   0.89 (0.70-1.14)   0.37
  Poland                                      467      187      0.30               0.26   1.00 (0.72-1.37)   0.99
  ARUK                                        642      730      0.33               0.34   0.98 (0.83-1.17)   0.85
  ADGC/Hollingworth^d^                        18,123   18,096                                                3.6 × 10^-12^
  Mayo2/ADGC/Hollingworth^e^                  20,661   22,148                                                1.8 × 10^-13^

Abbreviations: MAF, minor allele frequency; OR, odds ratio for the minor allele; 95% CI, 95% confidence interval

^a^The numbers shown for the series in the Naj *et al*. and Hollingworth *et al*. studies refer to the complete set analyzed. The numbers for the Mayo follow-up data refer to the number of samples successfully genotyped.

^b^MAFs were not reported for LOAD and control groups in the Naj *et al*. or Hollingworth *et al*. studies.

^c^The results shown here for the Mayo2 follow-up dataset combined and for the subseries were obtained using logistic regression adjusted for age, sex and *APOE ε 4*dosage. The Mayo2 follow-up dataset reported here is independent of that which was incorporated in the GWAS reported by Hollingworth *et al*. The results for each of the Mayo follow-up subseries (Jacksonville, Rochester, Autopsy-confirmed, Norway, Poland and ARUK) are listed immediately below the results for the Mayo2 follow-up dataset combined.

^d^Indicates Fisher\'s combined p-value for each individual GWAS in the Naj *et al*. study (Combined) and the Hollingworth *et al*. study.

^e^Indicates Fisher\'s combined p-value for each individual GWAS in the Naj *et al*. study (Combined), the Hollingworth *et al*. study and Mayo2 independent follow-up series.

In order to estimate the overall association of these five variants in our data combined with the previously published associations, we used Fisher\'s method to combine the p-values for all associations (Table [3](#T3){ref-type="table"}; Mayo2/ADGC/Hollingworth). We found that adding our data to those previously reported, increased the strength of evidence for all variants as LOAD risk modifiers (*CD2AP*: p = 6.5 × 10^-11^, *EPHA1*: p = 2.1 × 10^-15^, *ARID5B*rs2588969: p = 2.3 × 10^-9^, *ARID5B*rs4948288: p = 4.0 × 10^-4^, *CD33*: p = 1.8 × 10^-13^).

Discussion
==========

We report here successful replication of the association of two variants with LOAD in a large (n = 6,835), independent case-control study; rs11767557, which is located 3 kb upstream of *EPHA1*(p = 5 × 10^-4^) and rs3865444, which is located 373 bp upstream of *CD33*(p = 0.049). The ORs we observed in our meta-analyses (*EPHA1*= 0.88, *CD33*= 0.96) were comparable to those reported by both Naj *et al*. (*EPHA1*= 0.87, *CD33*= 0.89) and by Hollingworth *et al*. (*EPHA1*= 0.90, *CD33*= 0.89) such that the estimated p-values for association of these variants in all data (n \> 42,000) were an impressive 2.1 × 10^-15^for *EPHA1*and 1.8 × 10^-13^for *CD33*.

Although our meta-analyses showed successful replication of the association of the *ARID5B*variants rs2588969 (OR = 1.08, p = 0.046) and rs4948288 (OR = 1.11, p = 0.008) with a direction of association consistent with that reported by Hollingworth *et al*. (OR = 1.06 and 1.07, respectively), the associations did not survive adjustment for age-at-diagnosis/entry, sex and *APOE ε 4*status (p = 0.30 and 0.11, respectively). This covariate-dependent association could explain the opposing association reported by Naj *et al*. in their discovery (OR = 0.88) and replication (OR = 1.05) datasets for rs2588969; the only *ARID5B*variant they tested. Therefore, while estimation of the p-values for association of the *ARID5B*variants in all datasets combined were highly significant (rs2588969; p = 2.3 × 10^-9^and rs4948288; p = 4.0 × 10^-4^), interpretation of these associations should be treated with caution and should take into account the age-at-diagnosis/entry, sex and *APOE ε 4*dosage of the populations. Finally, although the estimated p-value for association of rs9349407 (located in intron 1of *CD2AP*) in all datasets was 6.5 × 10^-11^, there was no evidence for association of this variant in our dataset alone (OR = 0.97, p = 0.56).

Our Mayo2 collection of case-control series studies provided a total of 2,634 LOAD and 4,201 controls. Combining across studies to perform global tests of significance for additive genotypic trend tests gave us 80% power to detect ORs ranging from 1.17 (or 0.855) for variants with a minor allele frequency (MAF) of 0.2 to 1.13 (or 0.883) for variants with a MAF of 0.45 in controls. The study provided approximately 60% power to detect the OR of 1.11 that we report for *CD2AP*(MAF = 0.27).

Case-control studies such as this are not designed to ascertain whether the variants with reported association with LOAD risk are the functional variant but they can identify a linkage disequilibrium (LD) block within which a truly functional variant may reside. Our results indicate that the *EPHA1*and *CD33*variants represent excellent candidates for targeted deep sequencing or high density genotyping in order to define the locus further, followed by subsequent functional studies of nearby genes to elucidate the mechanism behind these associations. With the exception of rs9349407, which lies within intron 1of *CD2AP*, all of these variants lie within intergenic regions but for ease of the reader, we have thus far only referred to the nearest gene for each variant. This by no means signifies that these variants (or the functional variants in LD with them) are assumed to affect the expression or function of the nearest gene but may affect other nearby genes. Until it is known which gene underlies these associations, all nearby genes should be included in follow-up functional investigation (all genes that reside within 100 kb of these variants are listed in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1).

Conclusions
===========

Taken along with our previous publications \[[@B5],[@B18],[@B20],[@B21]\], we have now performed follow-up association studies of 25 of the top GWAS-identified candidate LOAD genes and successfully replicated the association of eleven variants (in or near *ABCA7, BIN1, CD33, CLU, CR1, EPHA1, GAB2, LOC651924, MS4A6A/4E*and *PICALM*), eight of which are currently ranked in the top ten (after *APOE*) on AlzGene. This recent success in replicating genetic association highlights the utility of multiple, large case-control follow-up studies to confirm the novel associations reported by large GWAS, thus confirming them as good candidate genes for functional follow-up studies.

Methods
=======

Ethics statement
----------------

Approval was obtained from the ethics committee or institutional review board of each institution responsible for the ascertainment and collection of samples. Written informed consent was obtained for all individuals that participated in this study.

Case-control subjects
---------------------

The Mayo2 case-control series consisted of Caucasian subjects from the United States ascertained at the Mayo Clinic Jacksonville, Mayo Clinic Rochester, or through the Mayo Clinic Brain Bank. Additional Caucasian subjects from Europe were obtained from Norway \[[@B22]\], Poland \[[@B23]\], and from six research institutes in the United Kingdom that are part of the Alzheimer\'s Research UK (ARUK) Network. Although the ARUK samples used in this follow-up do not overlap with those employed in the original GWAS publication by Hollingworth *et al*., the same subject/sample ascertainment methodology was followed. The ARUK series included here are from Bristol, Leeds, Manchester, Nottingham, Oxford and Southampton. Since the Manchester cohort only consisted of LOAD cases, the Manchester cases were combined with subjects in the Nottingham series.

Genotyping
----------

All genotyping was performed at the Mayo Clinic in Jacksonville using TaqMan^®^SNP Genotyping Assays in an ABI PRISM^®^7900HT Sequence Detection System with 384-Well Block Module from Applied Biosystems, California, USA. The genotype data was analyzed using the SDS software version 2.2.3 (Applied Biosystems, California, USA).

Statistical Analyses
--------------------

Meta-analysis of allelic association and Breslow-Day tests were performed using StatsDirect v2.5.8 software. Meta-analyses were performed using the results from each individual case-control series. Summary ORs and 95% CI were calculated using the DerSimonian and Laird (1986) random-effects model \[[@B24]\]. Breslow-Day tests were used to test for heterogeneity between populations. PLINK software \[[@B25]\] (<http://pngu.mgh.harvard.edu/purcell/plink/>) was used to perform logistic regression analysis under an additive model adjusting for age-at-diagnosis, sex and *APOE ε*4 dose as covariates. In our analysis of all series combined, series was included as an additional covariate. Since genotype counts were not reported for series included in the Naj *et al*. or Hollingworth *et al*. studies, we employed a Fisher combined test to combine p-values across series. Power calculations, based on a Mantel-Haenszel chi-square test that pooled across six different study groups, were obtained to estimate the detectable odds ratios for an ordinal effect using a range of minor allele frequencies spanning those expected from the candidate variants.

Abbreviations
=============

ABCA7: ATP-binding cassette, sub-family A (ABC1), member 7; AD: Alzheimer\'s disease; ADGC: Alzheimer\'s disease Genetic Consortium; APOE: apolipoprotein E; ARID5B: AT rich interactive domain 5B (MRF1-like); ARUK: Alzheimer\'s Research United Kingdom; BIN1: bridging integrator 1; Bp: base pair; CD2AP: CD2-associated protein; CD33: CD33 molecule; CI: confidence interval; CLU: clusterin; CR1: complement component (3 b/4 b) receptor 1 (Knops blood group); EPHA1: EPH receptor A1; GAB2: GRB2-associated binding protein 2; GERAD: Genetic and Environmental Risk in Alzheimer\'s Disease Consortium; GWAS: genome-wide association study; kb: kilobases; LD: linkage disequibrium; LOAD: late-onset Alzheimer\'s disease; MAF: minor allele frequency; MS4A4A: membrane-spanning 4-domains, subfamily A, member 4; OR: odds ratio; PICALM: phosphatidylinositol binding clathrin assembly protein; SD: standard deviation.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

*Study concept and design:*MMC and SGY. *Sample Collection and Diagnosis*: ARUK, DWD, JOA, MB, NRG-R, RCP, SBS, and ZKW. *Genotyping*: MMC and TAH. *DNA Sample Preparation*: GDB, ML and ZFG. *Analysis and interpretation of data:*JEC, KM, MMC, OB, SGY and VSP. *Drafting of the manuscript:*MMC and OB. *Critical revision of the manuscript for important intellectual content:*KM, MMC, OB, SGY and VSP. *Study supervision:*KM, MMC and SGY. All authors have read and approve the final manuscript.

Supplementary Material
======================

###### Additional file 1

**Table S1. Genes located within 100 kb of the five variants tested in this study**. Chr, chromosome. Base pair positions (bp) are relative to the NCBI Human Genome build 36.1. The position of the variant relative to the gene is given as 5\' (upstream from the gene\'s transcription start site) or 3\' (downstream from the gene\'s last exon). Distance indicates the number of base pairs from the variant position to the gene\'s nearest exon.

###### 

Click here for file

Acknowledgements and Funding
============================

We thank contributors, including the Alzheimer\'s disease centers who collected samples used in this study, as well as subjects and their families, whose help and participation made this work possible. We thank the members of the Alzheimer\'s Research UK (ARUK) consortium who contributed samples to the ARUK resource. This work was supported by grants from the US National Institutes of Health, NIA R01 AG18023 (NRG-R, SGY); Mayo Alzheimer\'s Disease Research Center, P50 AG16574 (RCP, DWD, NRG-R, SGY); Mayo Alzheimer\'s Disease Patient Registry, U01 AG06576 (RCP); and US National Institute on Aging, AG25711, AG17216, AG03949 (DWD). Samples from the National Cell Repository for Alzheimer\'s Disease (NCRAD), which receives government support under a cooperative agreement grant (U24AG21886) awarded by the National Institute on Aging (NIA), were used in this study. This project was also generously supported by the Robert and Clarice Smith Postdoctoral Fellowship (MMC); Robert and Clarice Smith and Abigail Van Buren Alzheimer\'s Disease Research Program (RCP, DWD, NRG-R, SGY) and by the Palumbo Professorship in Alzheimer\'s Disease Research (SGY). KM is funded by the Alzheimer\'s Research UK and the Big Lottery Fund. ZKW is partially supported by the NIH/NINDS 1RC2NS070276, NS057567, P50NS072187, Mayo Clinic Florida (MCF) Research Committee CR programs (MCF \#90052018 and MCF \#90052030), Dystonia Medical Research Foundation, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch (MCF \#90052031/PAU \#90052). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**The Alzheimer\'s Research UK Consortium:**Peter Passmore, David Craig, Janet Johnston, Bernadette McGuinness, Stephen Todd, Queen\'s University Belfast, UK; Reinhard Heun (now at Royal Derby Hospital), Heike Kölsch, University of Bonn, Germany; Patrick G. Kehoe, University of Bristol, UK; Nigel M. Hooper, Emma R.L.C. Vardy (now at University of Newcastle), University of Leeds, UK; David M. Mann, University of Manchester, UK; Kristelle Brown, Noor Kalsheker, Kevin Morgan, University of Nottingham, UK; A. David Smith, Gordon Wilcock, Donald Warden, University of Oxford (OPTIMA), UK, Clive Holmes, University of Southampton, UK.
